Zona incerta as a therapeutic target in Parkinson's disease

Ossowska K.

J Neurol. 2020 Mar;267(3):591-606. doi: 10.1007/s00415-019-09486-8. Epub 2019 Aug 2.

Mesenchymal Stem Cells with Granulocyte Colony-Stimulating Factor Reduce Stress Oxidative Factors in Parkinson's Disease

Ghahari L, Safari M, Rahimi Jaberi K, Jafari B, Safari K, Madadian M.

Iran Biomed J. 2020 Mar;24(2):89-98. doi: 10.29252/ibj.24.2.89. Epub 2019 Nov 2.

α-Arbutin Protects Against Parkinson's Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo

Ding Y, Kong D, Zhou T, Yang ND, Xin C, Xu J, Wang Q, Zhang H, Wu Q, Lu X, Lim K, Ma B, Zhang C, Li L, Huang W.

Neuromolecular Med. 2020 Mar;22(1):56-67. doi: 10.1007/s12017-019-08562-6. Epub 2019 Aug 10.

Differentiating Parkinson's disease motor subtypes using automated volume-based morphometry incorporating white matter and deep gray nuclear lesion load

Fang E, Ann CN, Maréchal B, Lim JX, Tan SYZ, Li H, Gan J, Tan EK, Chan LL.

J Magn Reson Imaging. 2020 Mar;51(3):748-756. doi: 10.1002/jmri.26887. Epub 2019 Jul 31.

Noradrenergic pathways of locus coeruleus in Parkinson's and Alzheimer's pathology

Singh S.

Int J Neurosci. 2020 Mar;130(3):251-261. doi: 10.1080/00207454.2019.1667799. Epub 2019 Oct 13.

Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs

Ahamadi M, Conrado DJ, Macha S, Sinha V, Stone J, Burton J, Nicholas T, Gallagher J, Dexter D, Bani M, Boroojerdi B, Smit H, Weidemann J, Chen C, Yang M, Maciuca R, Lawson R, Burn D, Marek K, Venuto C

Clin Pharmacol Ther. 2020 Mar;107(3):553-562. doi: 10.1002/cpt.1634. Epub 2019 Dec 5.

Early-stage Parkinson's patients show selective impairment in reactive but not proactive inhibition

Di Caprio V, Modugno N, Mancini C, Olivola E, Mirabella G.

Mov Disord. 2020 Mar;35(3):409-418. doi: 10.1002/mds.27920. Epub 2019 Nov 21.

GABAergic changes in the thalamocortical circuit in Parkinson's disease

van Nuland AJM, den Ouden HEM, Zach H, Dirkx MFM, van Asten JJA, Scheenen TWJ, Toni I, Cools R, Helmich RC.

Hum Brain Mapp. 2020 Mar;41(4):1017-1029. doi: 10.1002/hbm.24857. Epub 2019 Nov 13.

Mycobacterial immunomodulation and viral manipulation of neuronal copper efflux in the setting of sporadic Parkinson's disease: A multi - hit, outside - in hypothesis of its pathogenesis

Vavougios GD.

Med Hypotheses. 2020 Mar;136:109505. doi: 10.1016/j.mehy.2019.109505. Epub 2019 Nov 18.

Antibiotic exposure and risk of Parkinson's disease in Finland: A nationwide case-control study

Mertsalmi TH, Pekkonen E, Scheperjans F.

Mov Disord. 2020 Mar;35(3):431-442. doi: 10.1002/mds.27924. Epub 2019 Nov 18.

The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease

Shih TM, Sail KR, Jalundhwala YJ, Sullivan J, van Eijndhoven E, Zadikoff C, Marshall TS, Lakdawalla DN.

J Med Econ. 2020 Mar;23(3):297-307. doi: 10.1080/13696998.2019.1693383. Epub 2019 Nov 28.

Increased substantia nigra echogenicity correlated with visual hallucinations in Parkinson's disease: a Chinese population-based study

Li T, Shi J, Qin B, Fan D, Liu N, Ni J, Zhang T, Zhou H, Xu X, Wei M, Zhang X, Wang X, Liu J, Wang Y, Tian J.

Neurol Sci. 2020 Mar;41(3):661-667. doi: 10.1007/s10072-019-04110-z. Epub 2019 Nov 22.

GIP has neuroprotective effects in Alzheimer and Parkinson's disease models

Zhang ZQ, Hölscher C.

Peptides. 2020 Mar;125:170184. doi: 10.1016/j.peptides.2019.170184. Epub 2019 Nov 6.

Texture features of magnetic resonance images: A marker of slight cognitive deficits in Parkinson's disease

Betrouni N, Lopes R, Defebvre L, Leentjens AFG, Dujardin K.

Mov Disord. 2020 Mar;35(3):486-494. doi: 10.1002/mds.27931. Epub 2019 Nov 23.

MiR-29c protects against inflammation and apoptosis in Parkinson's disease model in vivo and in vitro by targeting SP1

Wang R, Yang Y, Wang H, He Y, Li C.

Clin Exp Pharmacol Physiol. 2020 Mar;47(3):372-382. doi: 10.1111/1440-1681.13212. Epub 2019 Dec 15.